Navigation Links
Doyle Raizner Pradaxa Case Chosen for Bellwether Early Trial Consideration
Date:7/30/2013

(PRWEB) July 30, 2013

As progress continues in the Pradaxa multi district litigation (MDL), the bellwether case selection process has concluded with one of Doyle Raizner’s cases being chosen. Doyle Raizner’s case is one of 16 cases out of approximately 871 currently pending cases that were selected to move into the bellwether case-specific discovery phase. After the conclusion of case-specific discovery, Presiding Judge David Herndon will select four of the 16 cases to proceed to trial on August 11, 2014, November 3, 2014, January 5, 2015, and February 16, 2015. Judge Herndon’s selection of the four trial cases will occur on or before November 22, 2013.

Bellwether case selection is a judicial procedure where a select group of cases are presented for determining core issues, such as liability and damages, for the remaining cases. The outcome of the bellwether trials typically assists in the resolution of all cases within multi-district litigation. They also assist in expediting the trial process. In the case of Pradaxa litigation Judge Herndon promised an expedited process due to the age of the plaintiffs, among other factors.

“The patient whose case was selected for the bellwether selection suffered a near fatal episode of gastrointestinal bleeding just two weeks after her initial dose of Pradaxa,” said Patrick Dennis, the Doyle Raizner partner who manages the firm’s pharmaceutical docket.

Pradaxa litigation was consolidated into a MDL in August 2012 in the Southern District of Illinois, a federal court. [Docket No. 3:13-cv-50028-DRH-SCW] The court will handle claims that the blood thinner, Pradaxa, has serious and often deadly adverse side effects, including an increased risk of gastrointestinal and other bleeds, which were not properly communicated by Boehringer Ingelheim to healthcare professionals or patients. The drug is often prescribed to elderly patients to reduce the risk of stroke in people with atrial fibrillation. Compounding, a possible internal bleeding risk is the lack of an antidote to stop Pradaxa’s internal bleeding side effect. No antidote exists because Pradaxa was rushed to market before Boehringer Ingelheim took efforts to develop an antidote to protect patients taking this drug. As a result, many takers of Pradaxa have suffered from hemorrhages and deaths. The large number of complaints and impending personal injury cases against Pradaxa moved it to the top of 2011’s most dangerous drug report issued by the Institute for Safe Medication Practices, January 12, 2012.

To learn more about the firm and their part in Pradaxa litigation, please visit http://www.PradaxaLitigation.com.

About Doyle Raizner LLP:

Doyle Raizner LLP is a national personal injury litigation firm with main offices in Houston, Texas and Phoenix, Arizona. The firm's attorneys specialize in helping victims’ secure fair compensation for injuries or the death of a loved one.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10937550.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Bleeding Litigation
2. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
3. Pradaxa Lawsuit Attorneys at Wright & Schulte LLC Report on Scheduling of Bellwether Trials in Federal Pradaxa Bleeding Lawsuits
4. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes New Study Linking Pradaxa to Increased Heart Attack Risk
5. New Lawsuit on Pradaxa Bleeding: Now, AttorneyOne Can Provide Advice
6. New Study Casts Doubt on FDA Pradaxa Conclusions
7. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Side Effects Litigation
8. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Pradaxa Bleeding Claims Pending in Federal Litigation Now Exceed 1,000
9. Latest Pradaxa Internal Bleeding Problem Allegation Lawsuits Update; Resource4thePeople Reports Judge Schedules Important Hearing
10. New Lawsuit on Alleged Pradaxa Wrongful Death: Now, AttorneyOne Can Provide Advice
11. Pradaxa Lawsuits Move Ahead As Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the ... will be an opportunity for area-residents to celebrate two great years while also ...
(Date:3/27/2017)... ... March 27, 2017 , ... The homeowner improvement and repair market ... utilizing DIY and unlicensed contractors for renovations is also on the rise. Per a ... 2015, and of those, 42% failed to use a licensed contractor.(2) The risks associated ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician ... 100 Award, a prestigious award honoring the top influencers on RealSelf—the most trusted ... connect with doctors and clinics. , In 2016, more than 82 million people ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce ... large subjects. The ELITE DXA has an active scan window, which is more than ... to fit in the scan area could not undergo an accurate total body bone density ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its ... time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics ... trauma education developed in cooperation with the American College of Surgeons to promote ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... HAYWARD, Calif. , March 27, 2017  Impax ... Directors has appointed Paul M. Bisaro as ... of the Company,s Board, effective March 27, 2017. Mr. ... has served as Interim President and Chief Executive Officer ... years of generic and branded pharmaceutical experience, Mr. Bisaro, ...
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
(Date:3/27/2017)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... across multiple therapeutic areas, today announced that Amit Munshi , ... corporate update at the 16th Annual Needham Healthcare Conference on ... place April 4-5, 2017 at the Westin New York Grand ... A live audio webcast of the presentation will ...
Breaking Medicine Technology: